Mupet
The purpose of this study is to determine, whether there is clinical benefit of using
fdg-PET/CT (F-18-fluorodeoxyglucose- positron emission tomography/computed
tomography)compared to contrast-enhanced CT in primary treatment of advanced epithelial
ovarian cancer (EOC)
- Objectives
- the impact of preoperative PET/CT compared to CT on EOC stage definition
- to compare the value of preoperative PET/CT, CT and laparoscopy in intra-abdominal
tumour assessment. Laparotomy findings evaluated by surgeon and histopathologic
results serve as the reference standard.
- to compare serum markers HE4(human epididymis protein 4) and CA125 (cancer antigen
125) with FDG-PET/CT and CT in treatment response evaluation during neoadjuvant
chemotherapy and primary treatment of EOC
- to compare FDG PET/CT based treatment response evaluation with RECIST and GCIG
criteria
- Methods
- All the patients will undergo FDG-PET/CT prior surgery, after possible neoadjuvant
chemotherapy (NACT) and 4 weeks after completion of primary platinum-based
chemotherapy.
- CA125 and HE4 levels are measured pre-operatively, with every chemotherapy cycle
and regularly during follow-up until 1st disease relapse
Oct 31,2009
Female
18 Years
79 Years
18 Years
79 Years
150